Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Boehringer Ingelheim
Julphar
Fuji
Harvard Business School
Dow
Colorcon
UBS
Chinese Patent Office

Generated: July 20, 2018

DrugPatentWatch Database Preview

Aprepitant - Generic Drug Details

see a sample report or, see our see our flat-rate plans

« Back to Dashboard

What are the generic drug sources for aprepitant and what is the scope of aprepitant freedom to operate?

Aprepitant
is the generic ingredient in three branded drugs marketed by Glenmark Pharms Sa, Sandoz, Merck, Heron Theraps Inc, and Msd Merck Co, and is included in five NDAs. There are seven patents protecting this compound and four Paragraph IV challenges. Additional information is available in the individual branded drug profile pages.

Aprepitant has ninety-four patent family members in forty-four countries.

There are twenty-three drug master file entries for aprepitant. Six suppliers are listed for this compound.
Synonyms for aprepitant
(1R,2R,3R)-Aprepitant
170729-80-3
1NF15YR6UY
221350-96-5
3-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-1H-1,2,4-triazol-5(4H)-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-Delta(2)-1,2,4-triazolin-5-one
3-(((2R,3S)-3-(p-Fluorophenyl)-2-(((alphaR)-alpha-methyl-3,5-bis(trifluoromethyl)benzyl)oxy)morpholino)methyl)-delta(sup 2)-1,2,4-triazolin-5-one
3-[((2R,5-bis(trifluoromethyl)benzyl]oxy}morpholino)methyl]-.delta.2-1,2,4-triazolin-5-one
3-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,4-dihydro-1,2,4-triazol-5-one
3-[2-{1-[3,5-di(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)-1,4-oxazinan-4-ylmethyl]-4,5-dihydro-1H-1,2,4-triazol-5-one
3-{[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl}-4,5-dihydro-1H-1,2,4-triazol-5-one
3H-1,2,4-Triazol-3-one, 5-(((2R,3S)-2-((1R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-
3H-1,2,4-Triazol-3-one, 5-((2-(1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)-4-morpholinyl)methyl)-1,2-dihydro-, (2R-(2alpha(R*),3alpha))-
3H-1,4-Triazol-3-one, 5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-
5-(((2R,3S)-2-((R)-1-(3,5-bis(trifluoromethyl)phenyl)ethoxy)-3-(4-fluorophenyl)morpholino)methyl)-2H-1,2,4-triazol-3(4H)-one
5-[(2R,3S)-2-[(R)-1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-3-(4-fluoro-phenyl)-morpholin-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one
5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(Trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)-4-morpholinyl]methyl]-1,2-dihydro-3H-1,2,4-triazol-3-one
5-[[(2R,3S)-2-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy]-3-(4-fluorophenyl)morpholin-4-yl]methyl]-1,2-dihydro-1,2,4-triazol-3-one
5-[2-[1-(3,5-Bis-trifluoromethyl-phenyl)-ethoxy]-3-(4-fluoro-phenyl)-morpholin-4-ylmethyl]-2,4-dihydro-[1,2,4]triazol-3-one
5-{[(2R,3S)-2-{(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethoxy}-3-(4-fluorophenyl)morpholin-4-yl]methyl}-2,4-dihydro-3H-1,2,4-triazol-3-one
729A803
AB01274775_02
AB01274775-01
AB01275535-01
ABP000600
AC1OCFCG
AK322012
AKOS015895498
AKOS015969344
AOB6779
Aprepitant (JAN/USAN/INN)
Aprepitant (MK-0869 L-754030)
Aprepitant (MK-0869)
Aprepitant [USAN:INN:JAN]
Aprepitant [USAN]
Aprepitant,MK-0869, L-754030, Emend
Aprepitant(MK-0869)
aprepitantum
AS-14638
ATALOFNDEOCMKK-OITMNORJSA-N
BCP9000312
BDBM50220136
BRD-K52827117-001-01-6
C21555
C23H21F7N4O3
CCG-220747
CHEBI:499361
CHEMBL1471
Cinvanti
CS-0487
CTK4D3687
D02968
D0GU4K
DB00673
Emend
Emend (TN)
eMende
EX-A212
GTPL3490
HMS2090N12
HY-10052
I06-1151
L 754030
L-754030
L982
MK 0869
MK 869
MK-0869
MK-869
MK-869, L-754030, Emend, Aprepitant
MK0869
MLS006011068
MolPort-006-392-367
MolPort-009-679-399
NSC-748825
NSC748825
ONO 7436
ONO-7436
Q-200647
RL02193
s1189
SCHEMBL264924
SMR002530053
SR-05000001531
SR-05000001531-1
UNII-1NF15YR6UY
W-5373
ZINC27428713

US Patents and Regulatory Information for aprepitant

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Sandoz APREPITANT aprepitant CAPSULE;ORAL 090999-001 Sep 24, 2012 AB RX No No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-002 Mar 26, 2003 AB RX Yes Yes ➤ Try a Free Trial ➤ Try a Free Trial Y ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 AB RX Yes No ➤ Try a Free Trial ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Expired US Patents for aprepitant

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-001 Mar 26, 2003 ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Merck EMEND aprepitant CAPSULE;ORAL 021549-003 Jun 30, 2006 ➤ Try a Free Trial ➤ Try a Free Trial
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents for aprepitant

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
6,229,010 Polymorphic form of a tachykinin receptor antagonist ➤ Try a Free Trial
6,432,953 Polymorphic form of a tachykinin receptor antagonist ➤ Try a Free Trial
6,583,142 Polymorphic form of a tachykinin receptor antagonist ➤ Try a Free Trial
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

see a sample report or, see our see our flat-rate plans

Supplementary Protection Certificates for aprepitant

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2004 Austria ➤ Try a Free Trial PRODUCT NAME: APREPITANT, GEGEBENENFALLS IN FORM EINES PHARMAZEUTISCH ANNEMBAREN SALZES; REGISTRATION NO/DATE: EU/1/03/262/001 - EU/1/03/262/006 20031111
C/GB08/021 United Kingdom ➤ Try a Free Trial PRODUCT NAME: FOSAPREPITANT AND PHARMACEUTICALLY ACCEPTABLE SALTS THEREOF, IN PARTICULAR THE BIS(N-METHYL-D-GLUCAMINE)SALT; REGISTERED: UK EU/1/07/437/001 20080111; UK EU/1/07/437/002 20080111
C0010 France ➤ Try a Free Trial PRODUCT NAME: APREPITANT; REGISTRATION NO/DATE: EU/1/03/262/001 20031111
2004002 Lithuania ➤ Try a Free Trial PRODCUT NAME: 5-[[(2R,3S)-2-[(1R)-1-[3,5-BIS(TRIFLUORMETIL)FENIL]ETOKSI]-3-(4-FLUORFENIL)-4-MORFOLINIL]METIL]-1,2-DIHIDRO-3H-1,2,4-TRIAZOL-3-ONAS (APREPITANTAS); REGISTRATION NO./DATE: EU/1/03/262/001-006/20031111
Supplementary Protection Certificate SPC Country SPC Expiration SPC Description

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Chinese Patent Office
US Department of Justice
Daiichi Sankyo
Merck
Citi
Johnson and Johnson
AstraZeneca
Harvard Business School
Argus Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.